CSBRChampions Oncology, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.95 · now $4.95 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CSBR has typically landed between $3.99 and $6.22 — a range of −19.4% to +25.6% from the issuance price $4.95.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,904 overlapping 1 month windows · 2007-02-022026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.95) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CSBR has typically landed a month from the 2026-09-16 close of $4.95 — the range is history, not a prediction.

$3.99worst · -19.4%$6.22best · +25.6%
  • now $4.95 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.85 (-2.0%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $4.48$5.22
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.99$6.22
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,904 windows spanning 2007-02-02 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2007-12-24−52.9%−52.9%+0.0%
2011-02-18−52.6%−52.6%+0.0%
2008-09-24−50.0%−60.0%+0.0%
3 best
2007-09-25+296.2%+0.0%+296.2%
2007-09-24+278.4%+0.0%+278.4%
2007-09-26+267.9%+0.0%+296.2%

4,904 overlapping windows · 2007-02-022026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
42%
+8.3%
n=19
Feb
58%
+0.6%
n=19
Mar
35%
+1.5%
n=20
Apr
40%
−1.8%
n=20
May
45%
+4.9%
n=20
Jun
50%
+5.0%
n=20
Jul
35%
−3.9%
n=20
Aug
35%
−1.3%
n=20
Sep
55%
+8.7%
n=20
Oct
32%
+1.8%
n=19
Nov
37%
−0.9%
n=19
Dec
58%
+13.4%
n=19

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$8$5↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

18 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2025-11-05TOBIN SCOTT RdirectorAward / grant25,46025,460Form 4
2025-11-05ACKERMAN JOELdirectorAward / grant21,21621,216Form 4
2025-11-05SIDRANSKY DAVIDdirectorAward / grant21,21621,216Form 4
2025-11-05Mendelson Daniel NewmandirectorAward / grant13,79013,790Form 4
2025-11-05Breitfeld Philip P.directorAward / grant13,79013,790Form 4
2025-10-30ACKERMAN JOELdirectorOption exercise94,4051,056,539Form 4
2025-10-30ACKERMAN JOELdirectorOption exercise94,4050Form 4
2025-07-16Brainin Robert LawrencedirectorAward / grant225,000299,163Form 4
2025-07-16Brainin Robert LawrencedirectorAward / grant150,000574,163Form 4
2025-07-16Brainin Robert LawrencedirectorAward / grant100,000674,163Form 4
2025-07-16Brainin Robert LawrencedirectorAward / grant100,000774,163Form 4
2025-07-16Brainin Robert LawrencedirectorAward / grant62,500361,663Form 4
2025-07-16Brainin Robert LawrencedirectorAward / grant62,500424,163Form 4
2025-03-25Breitfeld Philip P.directorOther acquisition4,1505,717Form 4
2024-11-12Brainin Robert LawrencedirectorAward / grant23,03074,163Form 4
2023-11-03Brainin Robert LawrencedirectorAward / grant19,07051,133Form 4
2022-11-01Brainin Robert LawrencedirectorAward / grant14,13032,063Form 4
2021-11-05Brainin Robert LawrencedirectorAward / grant9,90117,933Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.